LONG-TERM OUTCOMES IN BREAST CANCER PATIENTS AFTER COMPLEX TREATMENT WITH ADJUVANT RADIATION THERAPY
Abstract
The study included 103 patients with stage T1–3N0–3M0 breast cancer who received multimodality treatment including neo- and adjuvant chemotherapy according to CMF and CAF schedules, hormonal therapy, radical mastectomy and adjuvant radiation therapy. All patients were divided into two groups depending on the volume of postoperative radiation therapy. Group I patients (n=48) received 40–44 Gy external radiation therapy to the areas of potential regional spread. Group II patients (n-55) additionally received radiation therapy delivered to postoperative scar area at a total dose of 38–44 isoGy. The comparative analysis of long-term results showed a significant decrease in the rate of local recurrences and increase in the 5-year recurrence-free and overall survival rates in the group of breast cancer patients who received adjuvant radiation therapy to the areas of potential regional spread and postoperative scar. In order to plan adequate radiotherapy
and to minimize local radiation-induced reactions, it is necessary to consider clinical and morphological prognostic factors.
and to minimize local radiation-induced reactions, it is necessary to consider clinical and morphological prognostic factors.
About the Authors
K. A. Simonov
Cancer Research Institute, SB RAMS, Tomsk
Russian Federation
Russian Federation
Zh. A. Startseva
Cancer Research Institute, SB RAMS, Tomsk
Russian Federation
Russian Federation
E. M. Slonimskaya
Cancer Research Institute, SB RAMS, Tomsk, Siberian State Medical University, Tomsk
Russian Federation
Russian Federation
References
1. Геворкян В.С. Современные возможности внутритканевой лучевой терапии в комбинированном и комплексном лечении рака молочной железы центральной и медиальной локализации: Автореф. дис. … канд. мед. наук. М., 2008. 23 с.
2. Жогина Ж.А., Мусабаева Л.И., Слонимская Е.М. Показания к выбору объема адъювантной лучевой терапии при радикальной мастэктомии у больных раком молочной железы // Сибирский онкологический журнал. 2005. № 3 (15). С. 3–10.
3. Жогина Ж.А., Слонимская Е.М., Мусабаева Л.И. Влияние клинико-морфологических факторов на течение и прогноз ранних форм рака молочной железы // Сибирский онкологический журнал. 2003. № 3 (7). С. 7–10.
4. Пасов В.В. Патогенетические механизмы развития местных лучевых повреждений у больных раком молочной железы (обзор) // Мед. радиология и рад. безопасность. 2002. Т. 47, № 1. С. 61–67.
5. Ceilley E., Jagsi R., Goldberg S. et al. Radiotherapy for invasive breast cancer in North America and Europe: results of a survey // Int. J. Radiat. Oncol. Biol. Phys. 2005. Vol. 61. (2). P. 365–367.
6. Clarke M., Collins R., Darby S. et al. Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomized trials // Lancet. 2005. Vol. 366. Р. 2087–2106.
7. Gebski V., Lagleva M., Keech A. et al. Survival effects of postmastectomy adjuvant radiation therapy using biologically equivalent doses: A clinical perspective // J. Natl. Cancer Inst. 2006. Vol .98. Р. 26–38.
8. Giordano S.H., Kuo Y.F., Freeman J.L. et al. Risk of cardiac death after adjuvant radiotherapy for breast cancer // J. Natl. Cancer Inst. 2005. Vol. 97. Р. 419–424.
9. Gnant M., Harbeck N., Thomssen C. St. Gallen 2011: Summary of the Consensus Discussion // Breast Care (Basel). 2011. Vol. 6 (2). P.136–141.
10. Huang E.H., Tucker S., Strom E.A. et al. Postmastectomy radiation improves local-regional control and survival in patients with locally advanced breast cancer treated with neoadjuvant chemotherapy and mastectomy // J. Clin. Oncol. 2004. Vol. 22. Р. 4639–4647.
11. Jagsi R., Raad R.A., Goldberg S. et al. Locoregional recurrence rates and prognostic factors for failure in node-negative patients treated with mastectomy: implications for postmastectomy radiation // Int. J. Radiat. Oncol. Biol. Phys. 2005. Vol. 62. Р. 1035–1039.
12. Kunkler I.H., Canney P., van Tienhoven G., Russell N.S. Elucidating the role of chest wall irradiation in «intermediate-risk» breast cancer: The MRC/EORTC SUPREMO trial // Clin. Oncol. (R Coll. Radiol.) 2008. Vol. 20. Р. 31–34.
13. Livi L., Meattini I., Di Cataldo V. Postmastectomy radiotherapy in breast cancer adjuvant treatment // Minerva Chir. 2010. Vol. 65 (5). Р. 527–536.
14. Nagao T., Kinoshita T., Tamura N. et al. Locoregional recurrence risk factors in breast cancer patients with positive axillary lymph nodes and the impact of postmastectomy radiotherapy // Int. J. Clin. Oncol. 2013. Vol. 18 (1). P. 54–61.
15. Nielsen H.M., Overgaard M., Grau C. et al. Study of failure pattern among high-risk breast cancer patients with or without postmastectomy radiotherapy in addition to adjuvant systemic therapy: long-term results from the Danish Breast Cancer Cooperative Group DBCG 82 b and c randomized studies // J. Clin. Oncol. 2006. Vol. 24 (15). Р. 2268–2275.
16. Olivotto I.A., Truong P.T., Chua B. Postmastectomy radiation therapy: who needs it? // J. Clin. Oncol. 2004. Vol. 22 (21). Р. 4237–4239.
17. Overgaard M., Hansen P.S., Overgaard J. et al. Postoperative radiotherapy in high-risk premenopausal women with breast cancer who receive adjuvant chemotherapy // N. Engl. J. Med. 1997. Vol. 337. Р. 949–955.
18. Overgaard M., Jensen J., Overgaard J. et al. Postoperative radiotherapy in high-risk postmenopausal breast-cancer patients given adjuvant tamoxifen: Danish Breast Cancer Cooperative Group DBCG 82c randomized trial // Lancet. 1999. Vol. 353. Р. 1641–1648.
19. Overgaard M., Nielsen H.M., Overgaard J. Is the benefit of postmastectomy irradiation limited to patients with four or more positive nodes, as recommended in international consensus reports? A subgroup analysis of the DBCG 82 b&c randomized trials // Radiother. Oncol. 2007. Vol. 82. Р. 247–253.
20. Recht A., Edge S., Solin L. et al. Postmastectomy radiotherapy guidelines of the American Society of Clinical Oncology // J. Clin. Oncol. 2001. Vol. 19. Р. 1539–1569.
21. Russell N., Kunkler I., Canney P. Postmastectomy Radiotherapy: Will the Selective Use of Postmastectomy Radiotherapy Study End the Debate? // J. Clin. Oncol. 2009. Vol. 27 (6). P. 996–1001.
22. Sharma R., Bedrosian I., Lucci A. et al. Present-day locoregional control in patients with t1 or t2 breast cancer with 0 and 1 to 3 positive lymph nodes after mastectomy without radiotherapy // Ann. Surg. Oncol. 2010. Vol. 17. P. 2899–2908.
23. Taylor M.E., Haffty B.G., Rabinovitch R. et al. ACR appropriateness criteria on postmastectomy radiotherapy expert panel on radiation oncology-breast // Int. J. Radiat. Oncol. Biol. Phys. 2009. Vol. 73 (4). P. 997–1002.
24. Truong P.T., Olivotto I.A., Kader H.A. et al. Selecting breast cancer patients with T1–T2 tumors and one to three positive axillary nodes at high postmastectomy locoregional recurrence risk for adjuvant radiotherapy // Int. J. Radiat. Oncol. Biol. Phys. 2005. Vol. 61. P. 1337–1347.
25. Truong P.T., Woodward W.A., Thames H.D. et al. The ratio of positive to excised nodes identifies high-risk subsets and reduces interinstitutional differences in locoregional recurrence risk estimates in breast cancer patients with 1–3 positive nodes: an analysis of prospective data from British Columbia and the M. D. Anderson Cancer Center // Int. J. Radiat. Oncol. Biol. Phys. 2007. Vol. 68. P. 59–65.
26. Wu S.G., He Z.Y., Li F.Y. et al. The clinical value of adjuvant radiotherapy in patients with early stage breast cancer with 1 to 3 positive lymph nodes after mastectomy // Chin. J. Cancer. 2010. Vol. 29. P. 668–676.
27. Yang P.S., Chen C.M., Liu M.C. et al. Radiotherapy can decrease locoregional recurrence and increase survival in mastectomy patients with T1 to T2 breast cancer and one to three positive nodes with negative estrogen receptor and positive lymphovascular invasion status // Int. J. Radiat. Oncol. Biol. Phys. 2010. Vol. 77. Р. 516–522.
Review
For citations:
Simonov K.A., Startseva Zh.A., Slonimskaya E.M. LONG-TERM OUTCOMES IN BREAST CANCER PATIENTS AFTER COMPLEX TREATMENT WITH ADJUVANT RADIATION THERAPY. Siberian journal of oncology. 2013;(2):30-35. (In Russ.)
Views:
437
Email this article 
